Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Male and female age 18 and above
Diagnosed with active rheumatoid arthritis (RA) by standard criteria at least 16 weeks before screening, have functional ACR class I-III
Have an inadequate response to methotrexate
In addition to an inadequate response to methotrexate have an inadequate response or intolerance to 1 but not more than 2 TNF inhibitors
Have a minimum of 6 swollen and 6 tender joints (from 66/68 joint count)
Have hsCRP of ≥ 0.8 mg/dL (8mg/L) \[by central laboratory values\] or an ESR ≥ 28 mm/hr
Willing to use effective birth control for the entire length of the study
You may not be if
Diagnosed with juvenile Rheumatoid Arthritis
Have been treated with other biologic treatment than a TNF inhibitor
Active systemic bacterial, viral or fungal infection or evidence of prior or current Hepatitis B or C infection or HIV infection, latent bacterial, viral or fungal infections
Have been treated with Intramuscular or Intra-articular glucocorticosteroids within 4 weeks of randomization
Taking Oral steroids at dose above 10 mg/day of prednisone (or prednisone equivalents)
Have other autoimmune disease other than RA like lupus, multiple sclerosis
Have significant concurrent medical condition at the time of screening or baseline visit
Clareo Health | Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
